Gyre Therapeutics (GYRE) Competitors $7.02 +0.10 (+1.45%) Closing price 04:00 PM EasternExtended Trading$7.04 +0.02 (+0.21%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. AMRX, NAMS, XENE, KNSA, RXRX, CNTA, ARWR, IDYA, BHC, and BLTEShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Xenon Pharmaceuticals (XENE), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), Bausch Health Cos (BHC), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Its Competitors Amneal Pharmaceuticals NewAmsterdam Pharma Xenon Pharmaceuticals Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Centessa Pharmaceuticals Arrowhead Pharmaceuticals IDEAYA Biosciences Bausch Health Cos Belite Bio Gyre Therapeutics (NASDAQ:GYRE) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Do institutionals & insiders hold more shares of GYRE or AMRX? 24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 10.0% of Gyre Therapeutics shares are owned by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate GYRE or AMRX? Amneal Pharmaceuticals has a consensus target price of $11.60, suggesting a potential upside of 44.10%. Given Amneal Pharmaceuticals' higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, GYRE or AMRX? Gyre Therapeutics has higher earnings, but lower revenue than Amneal Pharmaceuticals. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$100.64M6.54$12.09M$0.02351.00Amneal Pharmaceuticals$2.83B0.89-$116.89M$0.01805.00 Does the media refer more to GYRE or AMRX? In the previous week, Amneal Pharmaceuticals had 22 more articles in the media than Gyre Therapeutics. MarketBeat recorded 23 mentions for Amneal Pharmaceuticals and 1 mentions for Gyre Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 0.59 beat Gyre Therapeutics' score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Is GYRE or AMRX more profitable? Gyre Therapeutics has a net margin of 7.20% compared to Amneal Pharmaceuticals' net margin of -0.46%. Gyre Therapeutics' return on equity of 9.73% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics7.20% 9.73% 7.66% Amneal Pharmaceuticals -0.46%-188.26%5.34% Which has more risk & volatility, GYRE or AMRX? Gyre Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. SummaryGyre Therapeutics beats Amneal Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$658.18M$2.96B$5.50B$9.55BDividend YieldN/A2.41%4.71%4.14%P/E Ratio351.1817.1828.7823.91Price / Sales6.54306.45438.3895.11Price / Cash35.5442.6035.6858.35Price / Book6.698.008.225.62Net Income$12.09M-$54.52M$3.25B$265.35M7 Day Performance-3.44%-0.87%-0.73%-0.89%1 Month Performance-13.76%13.63%5.52%4.98%1 Year Performance-34.94%11.57%28.79%23.50% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.0162 of 5 stars$7.02+1.4%N/A-31.7%$658.18M$100.64M351.1840News CoverageUpcoming EarningsAMRXAmneal Pharmaceuticals3.4765 of 5 stars$7.96+1.7%$11.60+45.7%+21.3%$2.45B$2.79B-198.958,100Trending NewsEarnings ReportNAMSNewAmsterdam Pharma3.4769 of 5 stars$21.66+1.8%$41.30+90.7%+36.3%$2.39B$47.14M-11.524Positive NewsEarnings ReportXENEXenon Pharmaceuticals3.0916 of 5 stars$33.16+8.7%$54.82+65.3%-17.1%$2.34B$9.43M-10.27210News CoverageUpcoming EarningsHigh Trading VolumeKNSAKiniksa Pharmaceuticals International3.4391 of 5 stars$32.95+3.0%$41.17+24.9%+37.2%$2.33B$423.24M823.96220RXRXRecursion Pharmaceuticals2.0613 of 5 stars$5.80+2.1%$7.00+20.7%-18.3%$2.31B$58.84M-3.28400News CoverageEarnings ReportCNTACentessa Pharmaceuticals3.1974 of 5 stars$16.08-4.3%$28.10+74.8%+68.4%$2.25B$6.85M-8.88200News CoverageUpcoming EarningsARWRArrowhead Pharmaceuticals3.8458 of 5 stars$16.47+3.4%$43.71+165.4%-34.3%$2.20B$545.21M-11.76400Upcoming EarningsAnalyst RevisionIDYAIDEAYA Biosciences4.2047 of 5 stars$25.00+3.0%$48.09+92.4%-34.8%$2.13B$7M-6.9680News CoverageEarnings ReportGap UpBHCBausch Health Cos4.5485 of 5 stars$5.78+1.1%$9.00+55.8%+14.1%$2.11B$9.63B22.2120,700Earnings ReportBLTEBelite Bio2.2514 of 5 stars$69.79+6.2%$96.67+38.5%+44.0%$2.09BN/A-51.3210Upcoming Earnings Related Companies and Tools Related Companies Amneal Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Xenon Pharmaceuticals Competitors Kiniksa Pharmaceuticals International Competitors Recursion Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors IDEAYA Biosciences Competitors Bausch Health Cos Competitors Belite Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredDebt Crisis Warning: How to Protect Your Wealth Before August 31stOn August 31st, the U.S. runs out of “extraordinary measures” to avoid default—and Washington insiders are alr...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GYRE Stock Alerts